Allogeneic CD19/BCMA CAR-T for relapsed or refractory B-cell and plasma cell cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, open-label dose-escalation pilot that plans to enroll about 21 patients with relapsed or refractory B-cell or plasma cell–derived malignancies. Participants receive an allogeneic CAR-T product (RN1101) engineered to target both CD19 and BCMA and are monitored closely for safety, cell expansion, persistence and antigen depletion. The primary goal is to test safety and feasibility, with secondary endpoints focused on clinical responses and exploratory endpoints assessing CAR-T kinetics and target cell clearance. The protocol includes standard toxicity monitoring and scheduled on-site follow-up visits to document adverse events and efficacy signals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Willingness to participate in the trial and provision of signed informed consent.
2. Patients diagnosed with B-lymphocyte or plasma cell-derived malignancies as per the 2017 revised WHO criteria, including acute B-lymphoblastic leukemia (B-ALL), and mature B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), mantle cell lymphoma (MCL), multiple myeloma (MM), etc.
3. Refractory or recurrent B-lymphocyte or plasma cell-derived malignancies, defined as failure to achieve complete remission after standard treatment, or relapse during follow-up after achieving remission with first-line or salvage therapy.
4. Patients with B-cell acute lymphoblastic leukemia (ALL) who have achieved hematologic remission but have persistent minimal residual disease (MRD).
5. According to the revised International Working Group (IWG) criteria, relapsed/refractory lymphoma patients must have at least one measurable lesion with a longest diameter ≥1.5 cm.
6. 18 Years and older, regardless of gender.
7. An expected survival of ≥12 weeks.
8. Serum total bilirubin level \< twice the upper limit of normal, serum creatinine level \< upper limit of normal, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< three times the upper limit of normal.
9. Absolute neutrophil count ≥0.5×10⁹/L, platelets ≥20×10⁹/L; for B-lymphocyte malignancies with definitive bone marrow involvement, no requirements for neutrophil and platelet counts.
10. ECOG performance status of 0 - 2.
11. Left ventricular ejection fraction (LVEF) ≥50% and no pericardial effusion.
12. At least 2 weeks have passed since the last treatment (radiotherapy, chemotherapy, monoclonal antibody therapy, or other treatments).

Exclusion Criteria:

1. Known allergies, hypersensitivity, intolerance, or contraindications to CD19/BCMA allogenic CAR-T or any components of the trial drugs (including fludarabine, cyclophosphamide, and rituximab), or a history of severe allergic reactions.
2. Recurrence after allogeneic hematopoietic stem cell transplantation with active graft - versus - host disease (GVHD) requiring steroid or immunosuppressive therapy.
3. Severe active infection.
4. Acquired or congenital immunodeficiency.
5. New York Heart Association (NYHA) Class Ⅲ or Ⅳ heart failure.
6. History of epilepsy or other central nervous system diseases.
7. Lymphoma with extranodal involvement of the brain, lungs, or gastrointestinal tract.
8. Other primary cancers, except:

   1. Non-melanoma skin cancer (e.g., basal cell carcinoma) cured by resection.
   2. Carcinoma in situ (e.g., cervical, bladder, or breast cancer) cured.
9. Systemic high-dose steroids within 2 weeks before treatment.
10. Pregnant, breastfeeding, or plans to become pregnant within 6 months.
11. Participation in another clinical trial within the past month.
12. Any situation the investigator deems may raise risks or interfere with trial results.

Where it's running

• Affiliated Hospital of Jiangsu University
  Zhenjiang, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Xiaoming Fei
• Email: feixiaomingujs@aliyun.com
• Phone: +86-1381512462752

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Using Fourth-Generation CAR-T to treat blood cancers

  This study is testing a new type of CAR-T therapy to see if it can safely help people with blood cancers like Multiple Myeloma and B-cell Lymphoma.

  Recruiting Phase 1 The Third Affiliated Hospital of Southern Medical University · Guangzhou, Guangdong · NCT06758713

• BCMA-TGFβ CAR-T Cells in Relapsed or Refractory Myeloma

  A one-arm phase 1 study tests a new BCMA-TGFβ CAR-T cell therapy to see if it is safe and provides signs of benefit in adults whose multiple myeloma has come back or persisted after prior treatments.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05976555

• CAR-T therapy outcomes and quality of life in older adults with B‑cell lymphoma

  This project will see how CAR‑T therapy affects older adults (age 60+) with relapsed or refractory B‑cell lymphomas, focusing on daily function and quality of life while they receive standard care.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York · NCT04300998

• Understanding CAR-T Toxicities After Cilta-Cel in Multiple Myeloma

  This observational study tests how patients with multiple myeloma respond to cilta-cel treatment by tracking toxicities and trying to spot biomarkers to guide care.

  Recruiting at 3 sites Icahn School of Medicine at Mount Sinai · San Francisco, California and 2 other locations · NCT07665307

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.